arsenic trioxide compound modulates multiple myeloma phenotypes: assessment on cell line models
نویسندگان
چکیده
recent evidences suggest that multiple myeloma phenotypes (mmps) are involved in the infiltration of multiple myeloma-affected marrow foci. in this study, the effects of arsenic trioxide on the invasive and angiogenic phenotypes of multiple myeloma (mm) cell line were assessed on a dose-response and time-course basis. multiple myeloma cell line, karpas 707, was treated with step-wise elevated concentrations of arsenic trioxide compound at 24, 48, and 72 h intervals. cytotoxicity was assessed with a colorimetric assay. potential antiinvasive phenotype was analyzed with mmp-2 zymography. to verify directly the anti angiogenic effect, f1 endothelial cell line was also treated with arsenic and the dose-dependent cytotoxicity was assessed with a colorimetric assay. apoptotic properties of arsenic trioxide compound were investigated using tunel assay. the significant dose-dependent inhibitory effects of arsenic trioxide on mmp-2 were seen at given concentrations. cytotoxicity analysis revealed much higher cell death than untreated cells (p< 0.01), both in karpas 707 and f1 endothelial cell lines. colectively, this study showed that arsenic trioxide might potentially elicit anti-invasive anti-angiogenesis properties in the treatment of myeloma dissemination process. in addition, the concurrent inhibition of mmps activity and endothelial cell proliferation could compose the scenario of neoangiogenesis inhibition in the marrow-infiltrated foci.
منابع مشابه
Trials of arsenic trioxide in multiple myeloma.
BACKGROUND Several reports on the use of arsenic trioxide (ATO), mainly in acute promyelocytic leukemia, have led to a renewed interest in ATO in the management of malignancies, especially those of hematologic origin such as multiple myeloma (MM). MM remains an incurable disease, with median survival rates of 4-6 years. Thus, newer treatments with good safety profiles are needed to improve the ...
متن کاملArsenic trioxide: an emerging therapy for multiple myeloma.
Arsenic trioxide can inhibit proliferation and induce apoptosis in multiple myeloma (MM) cells in vitro and in vivo. In addition to affecting tumor growth, arsenic trioxide has been shown to inhibit angiogenesis, suggesting that it may have significant potency in the treatment of MM. Based on these observations, the clinical efficacy of arsenic trioxide was evaluated in patients with advanced r...
متن کاملApoptotic effect of apoptin gene transduction on multiple myeloma cell line
Introduction: Following the first description of multiple myeloma (MM), as the second most prevalent hematologic malignancy, multiple promising advances have paved the way to increase the long-lasting complete remission for patients. In the era of the novel therapeutic approaches, the cloning of the apoptosis-inducing genes into the genome of malignant cells has attracted tremendous attention. ...
متن کاملVorinostat enhances chemosensitivity to arsenic trioxide in K562 cell line
Objective. This study aimed to investigate the chemosensitive augmentation effect and mechanism of HDAC inhibitor Vorinostat (SAHA) in combination with arsenic trioxide (ATO) on proliferation and apoptosis of K562 cells. Methods. The CCK-8 assay was used to compare proliferation of the cells. Annexin-V and PI staining by flow cytometry and acridine orange/ethidium bromide stains were used to de...
متن کاملAntitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration.
PURPOSE Arsenic trioxide (ATO) targets multiple pathways in malignant cells, resulting in the promotion of differentiation or in the induction of apoptosis. The antitumor activity of ATO on retinoblastoma was investigated. METHODS Human retinoblastoma cells were incubated with various ATO concentrations. The antiproliferative effect of ATO was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-dip...
متن کاملarsenic trioxide in patients with refractory multiple myeloma: a prospective, phase ii, single-arm study
multiple myeloma (mm) characterized by proliferation of plasma cells in bone marrow and production of monoclonal immunoglobulin's. recently, arsenic trioxide (ato), has been considered for treatment refractory mm. we assessed the safety and efficacy of ato for patients with refractory mm. a phase 2, study of arsenic trioxide was conducted in 12 mm patients, whose refractory to two standard ther...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
iranian journal of public healthجلد ۳۵، شماره ۱، صفحات ۱۷-۲۴
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023